Michaeline Daboul, Matthew Stephenson, and Linda D. Bentley are interviewed by Bloomberg BNA’s John T. Aquino. Learn what experts in the life sciences industry are saying about biopharma compliance to foreign bribery laws and the US FCPA in the age of Trump.
Find out what experts, including Michaeline Daboul, CEO of MMIS, thinks about the future of the foreign corruption law and its influence in the life sciences industry as President Donald J. Trump sets out to de-regulate business.
In my interview, Up in the Clouds, with Thanh Thanh Lam from ICT, I address the compliance regulations and business challenges pharmaceutical companies face now. Also, I discuss how new SaaS cloud based transparency solutions and HCP engagement SaaS compliance solutions are becoming industry standards. The interview focuses on compliance challenges in the life sciences industry. I explain the how MediSpend is designed to make it easier for life sciences companies to address compliance regulations and comply with current evolving laws.
Michaeline Daboul’s blog will feature original articles and the information I share is my way of giving back to our growing customer base, our employees and entrepreneurs like me. I’m often asked what I am reading, who inspires me, and what new products we are working on. Expect to have those questions answered and some thought provoking ideas presented in this blog.
As Trumpcare emerges what will happen to the Sunshine Act and the healthcare transparency ecosystem?
Will Trump repeal the ACA and along with it Open Payments aka the Sunshine Act? If sections of the ACA are repealed and Trumpcare replaces Obamacare, will Open Payments become more onerous or disappear? This post examines the evolution of Open Payments and the evolving healthcare transparency ecosystem which now includes 38 countries. How will Trump’s policies affect life sciences companies that operate in the US?